A study to investigate the effect on QTcF of Baxdrostat compared with placebo, using Moxifloxacin as a positive control, in healthy participants

Trial Identifier:	D6970C00004
Sponsor:	AstraZeneca
NCTID::	NCT06194032
Start Date:	February 2024
Primary Completion Date:	May 2024
Study Completion Date:	May 2024

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
DE	Berlin, DE, 14050

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.